GlobeNewswire

Aegex Collaborates with Verizon, Nokia, Guardian Centers on Unique Event

Dela

To Demonstrate IoT and Emergency Response Technologies

ATLANTA, June 07, 2017 (GLOBE NEWSWIRE) -- VerizonNokia and  Aegex Technologies LLC  have collaborated on a unique partner and user event at the Guardian Centers focused on demonstrating a secure Internet of Things (IoT) ecosystem and emergency response technologies in a "meta-scale" environment with realistic industrial and emergency response scenarios.

The event, Operation Convergent Response (#OCR2017) is being held June 7-8, 2017, at the Guardian Centers training facility in Perry, Ga., USA. It is the largest collaborative effort for learning about and testing IoT and emergency response solutions for very large and complex hazardous areas. In the case of industrial use, hazardous areas are those where equipment must be certified "intrinsically safe," or incapable of causing a spark that could ignite an explosion. For emergency response, cutting edge, "smart" technologies that can be used in highly explosive and critical environments, such as those being demonstrated at #OCR2017, can be life-saving.

This event will demonstrate that, whether in a highly combustible chemical manufacturing plant, a cityscape where a natural disaster has occurred, or a location where a terrorist attack takes place, a secure, software-defined-perimeter (SDP)-based, inter-connected and "intrinsically safe" ecosystem of platforms can significantly aid operations personnel or emergency teams in responding to situations appropriately and quickly while reducing risk to responders and citizens.

"Operation Convergent Response puts technology front and center in the crisis response arena," said Jeffrey Schweitzer, chief innovation architect, Business Products & New Business Innovation for Verizon. "Today's first responders and businesses have a broad array of technologies available to them to respond to a crisis situation. We thank our fellow technology experts for joining with us to showcase those capabilities."

"Nokia has been a key player in defining the future of the Public Safety industry," said Ricky Corker, Head of North America for Nokia, "Our technology innovations - many of which will be showcased at this event - are making mission-critical mobile broadband a reality for this important sector. We're pleased to partner with Verizon and Aegex to test the technologies that are most vital to emergency responders." 

"The combination of Verizon's and Nokia's ultra-secure network solutions with Aegex's intrinsically safe IoT equipment and systems will demonstrate how vital real-time data and communications are for any hazardous operation, including emergency scenarios," said Aegex CEO Thomas P. Ventulett. "We are excited to test our joint technologies in the world's premier realistic training facility at the Guardian Centers."

Verizon and Nokia are bringing together a global mix of corporate and government leaders to observe and learn how a secure software-defined network, rapidly deployable ad hoc network solutions, 4D visualization and other mission-critical solutions can resolve public/private sector interoperability and connectivity challenges in various real-world scenarios, even in bandwidth-constrained, GPS-denied environments, and even while under cyber-attack.

Aegex, developer of the first globally certified intrinsically safe Windows 10 tablet, the Aegex10 IS, and the world's first intrinsically safe IoT Platform for Hazardous Locations, is inviting its Channel, Technology and Strategic Partners, plus customers and industry professionals, to participate in this unique event. Collectively, they will demonstrate how an IoT solution and new technologies can be efficiently deployed under realistic conditions, including gas emissions, natural disasters, terrorism scenarios, and more, to improve operations and emergency response.

Using the Aegex IoT Platform to capture, transmit and analyze myriad data can help plant operators perform better and more safely, and can also aid first responders in their rescue and recovery efforts. Participants in the event will develop an understanding of how various and often unpredictable conditions can impact the sharing of information, and how consumers of that information can use it to make safer, more intelligent decisions, especially in critical moments, whether in manufacturing or public safety. 

Taking place at the largest privately held facility in the world for hazardous area simulation and disaster training, the June 7-8 event will include participants testing IoT sensors with the Aegex platform installed at the Guardian Centers. Applying life-saving rules used by military, security services, and industrial customers, experience simulations of real-life hazardous area scenarios that can immediately be applied to facilities and "smart" cities around the world. 

Participants may also choose to engage in optional activities with Guardian Centers trainers, including rappelling from buildings, target shooting, close quarters combat, and other exciting "mission-critical" activities.

About Verizon
Verizon Communications Inc. (NYSE:VZ) (Nasdaq:VZ), headquartered in New York City, has a diverse workforce of 161,000 and generated nearly $126 billion in 2016 revenues. Verizon operates America's most reliable wireless network, with 113.9 million retail connections nationwide. The company also provides communications and entertainment services over mobile broadband and the nation's premier all-fiber network, and delivers integrated business solutions to customers worldwide.

About Nokia
We create the technology to connect the world. Powered by the research and innovation of Nokia Bell Labs, we serve communications service providers, governments, large enterprises and consumers, with the industry's most complete, end-to-end portfolio of products, services and licensing.  From the enabling infrastructure for 5G and the Internet of Things, to emerging applications in virtual reality and digital health, we are shaping the future of technology to transform the human experience. www.nokia.com

About Guardian Centers
Guardian Centers owns and operates an advanced training center that delivers realistic training and exercises to enhance the operational readiness of response organizations.  Located in Perry GA, approximately 90 miles south of Atlanta, the center occupies 830 acres and includes 350 acres of a realistic urban operating environment. Clients include the U.S. Department of Defense, Department of State, Department of Homeland Security, National Guard Bureau, Federal Emergency Management Agency, U.S. AID, Office of Foreign Disaster Assistance and several international clients. For more information, visit http://guardiancenters.com/ or call +1 478-224-5700.

About Aegex Technologies LLC
With world headquarters in Atlanta, Ga., USA, European headquarters in Rotterdam, Netherlands, sales offices in Southampton, UK and Dubai, UAE, and distributors worldwide, Aegex provides intrinsically safe mobile and Internet of Things (IoT) solutions for hazardous locations in oil and gas, chemical, pharmaceutical, public safety and other industries with explosive environments. Aegex is the maker of the first globally certified intrinsically safe Windows 10 tablet and the first IoT Platform for Hazardous Locations, which can be used for real-time data and communications in hazardous locations where only specially designed equipment that will not ignite an explosion is permitted.

Contact Aegex for more details.

Watch the latest Aegex video to learn more.

press@aegex.com 
www.aegex.com 
LinkedIn 
Twitter 
Facebook 
Google+ 
Instagram 

Aegex Technologies, LLC
+1 470.242.4000
contact@aegex.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Aegex Technologies via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in October and November22.10.2018 16:00Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Announces Upcoming Investor Events in October and November Immunicum AB (publ; IMMU.ST) announced today that the Company will participate in and host investor events in October and November. At all events Carlos de Sousa, CEO of Immunicum, and other members of the management team, will provide a corporate presentation and be available for a question and answer session. BioStock Life Science Summit Date: October 25, 2018 Presentation Time: 18.50 Central European Time Venue: Medicon Village, Scheelevägen 2, Building 302-auditorium, Lund, Sweden Registration Link: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicum Investor Event - Gothenburg Date: October 29, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venue: First Hotel G, Nils Ericsonplatsen, 411 03 Gothenburg, Sweden Immunicum Investor Event - Stockholm Date: October 30, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venu

Immunicum AB (publ) meddelar kommande investerarevent under oktober och november22.10.2018 16:00Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) meddelar kommande investerarevent under oktober och november Immunicum AB (publ; IMMU.ST) meddelar i dag att bolaget kommer att anordna och delta i investerarträffar under oktober och november. Vid samtliga event kommer Carlos de Sousa, Immunicums VD, och övriga medlemmar av ledningsgruppen, att hålla en presentation av bolaget och vara tillgängliga för att svara på frågor. BioStock Life Science Summit Datum: 25 oktober 2018 Presentationstid: Kl. 18.50 CET Plats: Medicon Village, Scheelevägen 2, byggnad 302 - hörsalen, Lund Länk för registrering: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicums investerarevent - Göteborg Datum: 29 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: First Hotel G, Nils Ericsonplatsen, 411 03, Göteborg Immunicums investerarevent - Stockholm Datum: 30 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: Ingenjörshuset Citykonferensen, Plan 1, Malmski

Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress22.10.2018 12:45Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress -- Intratumoral behandling med ilixadencel, en cellbaserad, lagringsbar immunaktiverare, ger en synergistisk antitumöreffekt och förstärker effekten av behandling med anti-PD-1 och anti-CD137 i djurmodeller -- Immunicum AB (publ; IMMU.ST) presenterar under 2018 års ESMO kongress (European Society for Medical Oncology) prekliniska resultat som visar en synergistisk anti-tumöreffekt när bolagets ledande produkt ilixadencel ges i kombination med en checkpointhämmare eller immunaktiverare. Resultaten från studien, som presenteras på en poster, visar att intratumoralt administrerat ilixadencel kan förstärka anti-tumörsvar och överlevnad vid behandling med checkpointhämmare eller immunaktiverare. Detta visar på potentialen hos ilixadencel att bli en komplementerande verkningsmekanism till flera olika framtida im

Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 201822.10.2018 12:45Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 -- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model -- Immunicum AB (publ; IMMU.ST) announced today the presentation of preclinical results that showed anti-tumor synergy between its lead product ilixadencel and a checkpoint inhibitor or an immune enhancer in a poster at the European Society for Medical Oncology (ESMO) 2018 Congress. The results of the study highlight the ability of intratumoral ilixadencel to enhance anti-tumor response and survival of systemic checkpoint inhibitors (anti-PD-1) or immune enhancers (anti-CD137/4-1BB). This emphasizes the potential for ilixadencel in multiple future immuno-oncology combination strategies by incorporating complementary mech

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum